Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PLRS 18%
PLRS 15% Up , uptrend starts !
good work drluck , good luck to all !
0.10 , 0.10 , 0.10 !!!!!! go PLRS !!!!
MA 200 in 0.07
PLRS confenrence with amazing news tomorrow
0.042 7.55% UP
PLRS ready to fly
0.0380 X 0.0390 MA 50 0.0390 uptrend starts
Strong close above 0.04 look
Hill attack
Naked Shorts' days are numbered, see SEC response below:
Thank you for contacting the SEC.
As you may know, both the Commission and self-regulatory organizations
have been focusing for some time on short sale regulation. The
Commission recently adopted amendments to its rules governing short selling,
now consolidated in Regulation SHO. While naked short selling is not per
se illegal, Regulation SHO seeks to address the problem of manipulative
or abusive naked short selling, among other things. Recently, the
Commission voted to eliminate the "grandfather" clause of Regulation SHO in
order to further reduce the number of fails to deliver. The amendment
will be effective on October 15, 2007. For more information, please
see http://www.sec.gov/news/press/2007/2007-...
Please be assured that the Commission is committed to detecting and
prosecuting violations of the federal securities laws, including
violations of Regulation SHO; we cannot comment, however, on what specific
actions we may take. In the event that the SEC brings an action for
violation of Reg SHO or another provision of the federal securities laws,
that information will be made publicly available through a litigation or
administrative proceedings release.
I also note that, in general, a company’s continued appearance on the
threshold list does not necessarily constitute a violation of
Regulation SHO. Regulation SHO does not limit the amount of time a company can
be on the list. Regulation SHO includes a 13 day requirement for the
close-out of fail to deliver positions. Because a stock have been on
the list for more than 13 days does not necessarily mean that any
individual fail position has persisted for more than 13 days. The recent
amendments to Regulation SHO permit previously-excepted grandfather
positions that are threshold securities as of October 15, 2007 be closed out
within 35 settlement days. For more information on the rule’s
requirements, please see Section II.5 of the enclosed document from the Division
of Market Regulation entitled “Responses to Frequently Asked
Questions Concerning Regulation SHO” (December 17, 2004, updated July 6,
2007), http://www.sec.gov/divisions/marketreg/m...
Once again, thank you for your letter. I hope this information proves
helpful to you. If you have any questions, please do not hesitate to
contact Ann H. Sulzberg, an attorney on my staff, at (202) 551-6308.
Ann H. Sulzberg
Special Counsel
U.S. Securities and Exchange Commission
Office of Investor Education and Advocacy
(202) 551-6308
Naked Shorts' days are numbered, see SEC response below:
Thank you for contacting the SEC.
As you may know, both the Commission and self-regulatory organizations
have been focusing for some time on short sale regulation. The
Commission recently adopted amendments to its rules governing short selling,
now consolidated in Regulation SHO. While naked short selling is not per
se illegal, Regulation SHO seeks to address the problem of manipulative
or abusive naked short selling, among other things. Recently, the
Commission voted to eliminate the "grandfather" clause of Regulation SHO in
order to further reduce the number of fails to deliver. The amendment
will be effective on October 15, 2007. For more information, please
see http://www.sec.gov/news/press/2007/2007-...
Please be assured that the Commission is committed to detecting and
prosecuting violations of the federal securities laws, including
violations of Regulation SHO; we cannot comment, however, on what specific
actions we may take. In the event that the SEC brings an action for
violation of Reg SHO or another provision of the federal securities laws,
that information will be made publicly available through a litigation or
administrative proceedings release.
I also note that, in general, a company’s continued appearance on the
threshold list does not necessarily constitute a violation of
Regulation SHO. Regulation SHO does not limit the amount of time a company can
be on the list. Regulation SHO includes a 13 day requirement for the
close-out of fail to deliver positions. Because a stock have been on
the list for more than 13 days does not necessarily mean that any
individual fail position has persisted for more than 13 days. The recent
amendments to Regulation SHO permit previously-excepted grandfather
positions that are threshold securities as of October 15, 2007 be closed out
within 35 settlement days. For more information on the rule’s
requirements, please see Section II.5 of the enclosed document from the Division
of Market Regulation entitled “Responses to Frequently Asked
Questions Concerning Regulation SHO” (December 17, 2004, updated July 6,
2007), http://www.sec.gov/divisions/marketreg/m...
Once again, thank you for your letter. I hope this information proves
helpful to you. If you have any questions, please do not hesitate to
contact Ann H. Sulzberg, an attorney on my staff, at (202) 551-6308.
Ann H. Sulzberg
Special Counsel
U.S. Securities and Exchange Commission
Office of Investor Education and Advocacy
(202) 551-6308
Naked Shorts' days are numbered, see SEC response below:
Thank you for contacting the SEC.
As you may know, both the Commission and self-regulatory organizations
have been focusing for some time on short sale regulation. The
Commission recently adopted amendments to its rules governing short selling,
now consolidated in Regulation SHO. While naked short selling is not per
se illegal, Regulation SHO seeks to address the problem of manipulative
or abusive naked short selling, among other things. Recently, the
Commission voted to eliminate the "grandfather" clause of Regulation SHO in
order to further reduce the number of fails to deliver. The amendment
will be effective on October 15, 2007. For more information, please
see http://www.sec.gov/news/press/2007/2007-...
Please be assured that the Commission is committed to detecting and
prosecuting violations of the federal securities laws, including
violations of Regulation SHO; we cannot comment, however, on what specific
actions we may take. In the event that the SEC brings an action for
violation of Reg SHO or another provision of the federal securities laws,
that information will be made publicly available through a litigation or
administrative proceedings release.
I also note that, in general, a company’s continued appearance on the
threshold list does not necessarily constitute a violation of
Regulation SHO. Regulation SHO does not limit the amount of time a company can
be on the list. Regulation SHO includes a 13 day requirement for the
close-out of fail to deliver positions. Because a stock have been on
the list for more than 13 days does not necessarily mean that any
individual fail position has persisted for more than 13 days. The recent
amendments to Regulation SHO permit previously-excepted grandfather
positions that are threshold securities as of October 15, 2007 be closed out
within 35 settlement days. For more information on the rule’s
requirements, please see Section II.5 of the enclosed document from the Division
of Market Regulation entitled “Responses to Frequently Asked
Questions Concerning Regulation SHO” (December 17, 2004, updated July 6,
2007), http://www.sec.gov/divisions/marketreg/m...
Once again, thank you for your letter. I hope this information proves
helpful to you. If you have any questions, please do not hesitate to
contact Ann H. Sulzberg, an attorney on my staff, at (202) 551-6308.
Ann H. Sulzberg
Special Counsel
U.S. Securities and Exchange Commission
Office of Investor Education and Advocacy
(202) 551-6308
15th Oct new Sec rules ?
15th Oct new Sec rules for NAKED shorters ?
at 0.04 perhaps?
“This excellent event manages to integrate the many features of the developing regenerative medicine field, from basic science to translational medicine and the maturing biotech industry. It is internationally competitive with other forums and provides novel features of attraction to those in the community”
Dr Tim Allsopp, Chief Scientfiic Officer, Stem Cell Sciences
PLRS UP 18%
PLRs alert FOLKS 4 days for stem cells congress announce!
UP 21%
PLRS gapping HARD !!!!!!!! 20% UP !!!!
only 4 days for the BIG NEWS !!!!!
PLRS ....... HAIFA, Israel–(BUSINESS WIRE)–Pluristem Life Systems, Inc. (OTCBB: PLRS - News), a cell therapy company dedicated to the commercialization of stem cell products, today announced that it expects to submit the Pre-Investigational New Drug (Pre-IND) document describing the suggested clinical trial and the preclinical data to the FDA. Approval of the Pre-IND by the FDA precedes initiation of Phase I trials.
Pluristem recently presented a Pre-Pre-IND to the Center for Biologics Evaluation and Research (CBER), Office of Cellular, Tissue and Gene Therapies, a department in the Food and Drug Administration (FDA). The Pre-Pre-IND documented the final results of an animal model study using the Company’s innovative adjuvant cell therapy product based on PLacenta eXpanded Mesenchymal cells (PLX-I).
In the Pre-Pre-IND conference call following the submission of the document, the FDA team of experts and the Pluristem FDA team discussed the proposed structure of the clinical trial, and the pre-clinical data required to approve the initiation of Phase I clinical trials of PLX-I. The FDA and Pluristem agreed that the proposed structure of Pluristem’s Phase I study should document the safe use of PLX-I cells when combined with Umbilical Cord Blood (UCB), and how the combination could improve the treatment of blood disorders.
In the upcoming Pre-IND filing, Pluristem will present to the FDA CBER team the results of an additional agreed upon pre-clinical Animal trial. This additional pre-clinical animal trial will be performed on immune-deficient irradiated NOD-SCID mice which will be co-implanted with un-purified human umbilical cord blood cells and PLX-I. The conclusions will be held in comparison to Pluristem’s published Pre-clinical results that used CD34+ purified from human umbilical cord blood cells. This additional trial will determine the final structure of the pre-clinical data required for FDA approval of the IND application.
Mr. Zami Aberman, Pluristem CEO, stated: “We would like to thank the CBER team for the very productive discussion. We expect to demonstrate that the co-transplantation of PLX-I cell types are a promising manipulation that improves cord blood performance during the replacement of bone marrow transplants in adults. I believe that this new pre-clinical animal trial will help to finalize the required pre-clinical studies prior to moving to Phase I trials.”
Sellers RUN!!!!!! sorry shorters !!!!
PLRS 4 days for the announcement TIME TO BUY !!!
Pluristem to Present Promising PLX Data for Additional Clinical Indications at Prestigious International Conference on Regenerative Medicine
Pluristem Life Systems, Inc. (OTCBB:PLRS) (DAX:PJT), a bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of malignant, degenerative and auto-immune indications, announced today that it will present favorable results of pre-clinical studies of its proprietary PLacental eXpanded (PLX) cells for additional clinical indications on October 18th, at the “3rd World Congress on Regenerative Medicine” in Leipzig, Germany.
The Company previously announced that it had obtained favorable results in pre-clinical testing of PLX cells to treat limb ischemia, a potential market of over $1 Billion. PLX cells also showed in vitro to have properties that the Company believes gives these cells the potential to treat Parkinson's Disease.
Mr. Zami Aberman, Pluristem Chairman and CEO commented, “We are very proud that the Congress’ organizing committee found our research and studies valuable and chose Pluristem to present its findings at the Congress. We strongly believe that our PLX cells can be used to treat other diseases, such as central nervous system and cardiovascular disorders. We will soon submit the IND for our first product, PLX-I, for the treatment of blood cancers, to begin clinical trials early next year in the USA.”
TIME TO BUY !!!!!! 4 days for the announcement!!!!
HAIFA, Israel–(BUSINESS WIRE)–Pluristem Life Systems, Inc. (OTCBB: PLRS - News), a cell therapy company dedicated to the commercialization of stem cell products, today announced that it expects to submit the Pre-Investigational New Drug (Pre-IND) document describing the suggested clinical trial and the preclinical data to the FDA. Approval of the Pre-IND by the FDA precedes initiation of Phase I trials.
Pluristem recently presented a Pre-Pre-IND to the Center for Biologics Evaluation and Research (CBER), Office of Cellular, Tissue and Gene Therapies, a department in the Food and Drug Administration (FDA). The Pre-Pre-IND documented the final results of an animal model study using the Company’s innovative adjuvant cell therapy product based on PLacenta eXpanded Mesenchymal cells (PLX-I).
In the Pre-Pre-IND conference call following the submission of the document, the FDA team of experts and the Pluristem FDA team discussed the proposed structure of the clinical trial, and the pre-clinical data required to approve the initiation of Phase I clinical trials of PLX-I. The FDA and Pluristem agreed that the proposed structure of Pluristem’s Phase I study should document the safe use of PLX-I cells when combined with Umbilical Cord Blood (UCB), and how the combination could improve the treatment of blood disorders.
In the upcoming Pre-IND filing, Pluristem will present to the FDA CBER team the results of an additional agreed upon pre-clinical Animal trial. This additional pre-clinical animal trial will be performed on immune-deficient irradiated NOD-SCID mice which will be co-implanted with un-purified human umbilical cord blood cells and PLX-I. The conclusions will be held in comparison to Pluristem’s published Pre-clinical results that used CD34+ purified from human umbilical cord blood cells. This additional trial will determine the final structure of the pre-clinical data required for FDA approval of the IND application.
Mr. Zami Aberman, Pluristem CEO, stated: “We would like to thank the CBER team for the very productive discussion. We expect to demonstrate that the co-transplantation of PLX-I cell types are a promising manipulation that improves cord blood performance during the replacement of bone marrow transplants in adults. I believe that this new pre-clinical animal trial will help to finalize the required pre-clinical studies prior to moving to Phase I trials.”
The European Stem Cells & Regenerative Medicine Congress was a great success attracting 126 participants with eight sponsors and exhibitors. Of the 126 participants, 42% attended from biotech companies and 41% from research and academic institutes and 6% from the pharma industry.
THE COMPANY IS IN THE PROCESS OF DEVELOPING A QUALITY PORTFOLIO OF KEY RESOURCE PROPERTIES.
THE MERCEDES 100 PROJECT,
AREQUIPA GOLD TREND, PERU.
Brookmount’s principal resource property is situated in central Peru, 300 kilometres east of Lima along the geological trend hosting the prolific Arequipa Gold Deposit. The area is heavily mineralized, and for many years has been an important Gold/Silver/Copper/Zinc-producing area. Since 1994, the previous owners of the property have expended over $ 3,000,000 USD on this project, including additions to the existing underground structure with over 2,000 metres of raises, addits and shafts, as well as the construction of a road into the project site.
The Company obtained the rights to the Mercedes 100 Project in 2002. The property consists of six contiguous claims covering a total area of 2,611.31 hectares broken down as follows:
Mercedes 100 Claim 450.00 hectares
Celeste Claim 298.84 hectares
Celeste 2 Claim 218.58 hectares
Celeste 4 Claim 200.00 hectares
Nuevo Heraje Cuatro Claim 996.96 hectares
Nuevo Charo Claim 446.93 hectares
The existing infrastructures at the site are excellent. The property is easily accessed from Lima by paved mountain highway to Conception, then by good paved road to Santa Rosa de Ocopa. A good all-weather gravel road connects Ocopa with Satipo, a village in the Amazona river basin. The Mercedes 100 camp is 36 kilometres from Santa Rosa. A power line follows the main road past the mine and water for drilling is readily available. There is a narrow gauge railway connecting to the nearby smelting centres of La Oroya, 130 kilometres to the west.
The Mercedes 100 Project has sizeable reserves and an attractive payback rate. In order to further evaluate the project, the Company engaged the services of Guillermo Salazar, M.A., P. Geol., a geologist with extensive South American experience. His responsibilities include design of the initial drill program and the testing of the perceived geological potential of the property’s reserves. In a qualified report to the previous owners, Dr. Adrian Mann commented that the project was based on sound scientific principle and that “previous effort has been concentrated on the vein deposits, rather than the more massive potential of the disseminated deposits,” and that “the time has come to address the potential of these larger features.”
The following reserve values were assessed by Howard Coates of MPH Geological Consulting for Leader Mining Inc., the former owners in 1996:
Proven Reserves:
21,500 tonnes, unspecified grades
Potential & Prospective Reserves:
480,000 tonnes, unspecified grades
Possible Reserves:
1,950,000 tonnes, unspecified grades
Gold From 0.043 oz/t to 5.904 oz/t
Silver From 0.13 oz/t to 136.77 oz/t
Zinc From 0.30% to 18.61%
Lead From trace to 16.50%
This report also stated that the geological potential for the discover of additional polymetallic mineralization was good and that a fully integrated exploration program would include geological mapping, surface and underground channel sampling, airborne and ground geophysics, and geochemical and alteration studies, diamond drilling.
A recent cost study prepared by Paul Sterling of Kanada Mobile Services Ltd., indicated that “This Mercedes 100 Project Design & Cost Study indicates that the project is both technically and economically feasible.” The base case shows an internal rate of return at 143.2% and a net present value of $ 35.9 million USD at an 8% discount rate. The project will require further drilling and metallurgical test work in order to move the possible reserves into the probable/proven sector. A definition of the process design and metal recovery methods is also required.
ROCK CREEK, BRITISH COLUMBIA, CANADA
Brookmount’s newest property with significant volcanogenic massive magnetite-sulfide potential in south-eastern British Columbia, Canada, covering an area of approximately 3160 hectares known as the Rock Creek Property situated 10 kms southeast of Rock Creek, B.C. in the Greenwood Mining Division. The southern property boundary corresponds to the Canada - US border and is centered about 10 kms NW of the Crown Jewel open pit gold skarn deposit in Washington with a resource estimate in excess of 1.4 million ounces of gold that has cleared final hurdles and is scheduled to go into production this year. Recent work that has been carried out on a portion (Ket 28 occurrence) of the Rock Creek Property, an assortment of mapping, assessment reports, silt and soil geochemistry, air and ground geophysics, with several programs of shallow drilling has yielded significant and outstanding values. These values range from 1.9 g/t to 52.22 g/t of Gold. An aeromagnetic survey of the area conducted by Crownex Resources Corp. in 1989 indicates geological and geophysical characteristics similar to the Crown Jewel Deposit. A large and strong aeromagnetic anomaly characterizes both the Crown Jewel and the Rock Creek ground and suggests that the two are caused by the same kind of geological features. There are indications on the Rock Creek Property of a potential of volcanogenic massive magnetite-sulfide environment that may be very significant. The management of Brookmount feels that this acquisition is a significant move for the company in its desire to diversify its holdings with solid projects and add to shareholder value.
GOLD, SILVER, COPPER & ZINC MINERAL CLAIMS,
NORTHWESTERN QUEBEC, CANADA
Brookmount has also acquired a 100% interest in five mineral claims in Chazel Township near the mining town of Rouyn-Noranda in northwestern Quebec, Canada. The claims cover an area of 500 acres and are situated in an area well known for metal discoveries including Gold, Silver, Copper and zinc.
Resource Macamic Inc. and BHP Minerals (Canada) Ltd. have completed two extensive gold exploration programs on the company’s property here, indicating considerable potential for Gold and/or base metal deposits. The property represents an excellent opportunity for a joint venture or as a revenue source for a cash sale. The Company will re-examine previous exploration data in order to form its future exploration plans here.
15th Oct SEC naked short news ?
Time to BUY , thanks
PLRS: To Present Promising Data at Conference on Regenerative Medicine
Thursday October 11, 2007 08:46:16 EDT
Ridgeland, MS, OCT 11, 2007 (EventX/Knobias.com via COMTEX News Network) --
By Jay Everitt, jeveritt@knobias.com
Pluristem Life Systems, Inc. (PLRS) announced that it will present favorable results of pre-clinical studies of its proprietary PLacental eXpanded (PLX) cells for additional clinical indications on October 18th, at the "3rd World Congress on Regenerative Medicine" in Leipzig, Germany. The Company previously announced that it had obtained favorable results in pre-clinical testing of PLX cells to treat limb ischemia, a potential market of over $1 Billion. PLX cells also showed in vitro to have properties that the Company believes gives these cells the potential to treat Parkinson's Disease.
KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.
ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.
If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com
PLRS: To Present Promising Data at Conference on Regenerative Medicine
Thursday October 11, 2007 08:46:16 EDT
Ridgeland, MS, OCT 11, 2007 (EventX/Knobias.com via COMTEX News Network) --
By Jay Everitt, jeveritt@knobias.com
Pluristem Life Systems, Inc. (PLRS) announced that it will present favorable results of pre-clinical studies of its proprietary PLacental eXpanded (PLX) cells for additional clinical indications on October 18th, at the "3rd World Congress on Regenerative Medicine" in Leipzig, Germany. The Company previously announced that it had obtained favorable results in pre-clinical testing of PLX cells to treat limb ischemia, a potential market of over $1 Billion. PLX cells also showed in vitro to have properties that the Company believes gives these cells the potential to treat Parkinson's Disease.
KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.
ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.
If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com
Maxwell Media Marketing: Serious-Speculator.com Market Movers and Shakers for Thursday, October 11th PLRS
Thursday October 11, 2007 11:32:04 EDT
Oct 11, 2007 (M2 PRESSWIRE via COMTEX News Network) --
Maxwell Media Marketing: Serious Speculator's Market Movers and Shakers for today and tomorrow Pluristem Life Systems, Inc. (OTCBB:PLRS DAX:PJT)
Visit www.serious-speculator.com and register for our regular newsletter and email alerts. While there, also visit our new blog featuring insight and opinion regarding stocks on the move and market trends as well as our featured company, always of interest to serious speculators everywhere.
TODAY'S MOVERS AND SHAKERS
PLURISTEM LIFE SYSTEMS, INC. (OTCBB: PLRS ) Pluristem Life Systems, Inc. (OTCBB:PLRS DAX:PJT), is trading up on heavier than normal volume following the company's October 11, 2007 announcement that the bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of malignant, degenerative and auto-immune indications, will present favorable results of pre-clinical studies of its proprietary PLacental eXpanded (PLX) cells for additional clinical indications on October 18th, at the "3rd World Congress on Regenerative Medicine" in Leipzig, Germany. To read the entire story, click here http://biz.yahoo.com/bw/071011/20071011005551.html?.v=1
GENOIL, INC (OTCBB: GNOLF ) Genoil Inc. (CDNX:GNO ) (OTC BB:GNOLF ) is trading up 9% on heavy volume following their announcement October 11, 2007, of the appointments of Dr. Richard D. Chimblo as Manager of Global Business Development and Mr. Mohammed H. Al-Saif as Manager of Middle East Operations. Dr. Chimblo will be responsible for globally promoting the company's GHU heavy oil upgrading technology. Mr. Al-Saif will manage the business development activities of the company in the Middle East.
The company previously announced on Tuesday that the company had signed a binding Memorandum of Understanding with Stone & Webster International, Inc. (SWI), a wholly owned subsidiary of The Shaw Group Inc. (NYSE:SGR - News), pursuant to which SWI will provide marketing and technical assistance to Genoil in connection with further development of Genoil's Genoil Hydroconversion Upgrader ("GHU") technology. To read the entire stories, click here: http://finance.yahoo.com/q?s=gnolf.ob ABOUT SERIOUS-SPECULATOR.COM
Serious-Speculator.com is an Internet destination for investors seeking information on MicroCap and NanoCap companies. Our web site features companies in and includes Research Reports authored by our financial writers. We publish a newsletter to our subscribers, and we publish our "Movers and Shakers Alert" on a regular basis which we send out on the M2 Presswire from time to time identifying active and interesting microcap and nanocap companies
wait for the congress 19th but look MA50 and MA200
0.10 soon?
Plrs uptrend starts look !!!!! News out
No sellers !
Read this reports .................. http://www.mrg.net/reportView.php?repID=520
WALTHAM, Mass., Sept. 13 /PRNewswire/ -- Millennium Research Group
(MRG) has conducted a detailed analysis of the stem cell therapy market in
its US Markets for Stem Cell Therapies 2007 report. The analysis reveals
that although the market for stem cell therapies is in its infancy, it will
grow rapidly as products are approved in the US. Today, only two products
are on the market, but by 2017, almost 90 are expected to be available.
Stem cells have regenerative capabilities, and promise lasting
treatments for chronic disorders and potential cures for currently
'incurable' diseases. In 2007, the US stem cell therapies market earned
over $25 million in revenues, with only two orthopedic products available
in the US-Osiris Therapeutics' Osteocel, and Blackstone Medical's Trinity.
Aside from these two products, the development of the US market for stem
cell therapies is largely dependent on the success of clinical trials,
regulatory approval, and public acceptance. The first products in the
cardiovascular, diabetes, neurological, and tissue and organ stem cell
therapy markets are expected to enter the market between 2009 and 2013. The
entry of these products will open up a new realm of treatable disorders,
offering hope to patients and vast market potential.
"This market has almost everything going its way", says Chris Schutz,
senior analyst at MRG. "The big question mark however is the political and
public support. The prevalence of potentially treatable disorders, unmet
medical needs, rising health care costs, growth in the aging population,
and the success of the first stem cell therapy products are all factors
that will drive this market upward through 2017."
The US Markets for Stem Cell Therapies 2007 report includes coverage of
companies offering or developing products for the stem cell therapy market,
including Aastrom Biosciences, Advanced Cell Technologies, Arteriocyte,
Blackstone Medical, Cytori Therapeutics, Geron, Harvest Technologies,
International Stem Cell Corporation, and Osiris Therapeutics.
About Stem Cells
Stem cells are primal cells that are derived from highly proliferative
tissues. These cells are precursors to every organ, tissue, and cell in the
human body. Because of their universality and ability to repair or replace
damaged tissue, stem cells have the potential to cure injuries and diseases
such as orthopedic degenerative disease, cardiovascular disease, diabetes,
neurological disease, cancer, retinal disease, and other chronic and
autoimmune disorders.
About Millennium Research Group
Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc.
company (http://www.DecisionResources.com), is the global authority on medical
technology market intelligence and a leading provider of strategic
information to the health care sector. Focused solely on the medical
device, pharmaceutical, and biotechnology industries, the company provides
its clients with the benefits of its specialized industry expertise through
published reports and customized consulting services.
For more information, contact:
Amy Krohn
Millennium Research Group
416-364-7776 x101